(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
0.00% $ 1.320
Live Chart Being Loaded With Signals
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally...
Stats | |
---|---|
Volumen de hoy | 558 779 |
Volumen promedio | 2.52M |
Capitalización de mercado | 242.38M |
EPS | $0 ( 2024-03-04 ) |
Próxima fecha de ganancias | ( $-0.200 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.910 |
ATR14 | $0.00300 (0.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-05 | Deep Track Capital, Lp | Buy | 0 | Common Stock |
2024-02-20 | Zalevsky Jonathan | Sell | 9 014 | Common Stock |
2024-02-20 | Wilson Mark Andrew | Sell | 7 606 | Common Stock |
2024-02-20 | Robin Howard W | Sell | 20 033 | Common Stock |
2023-12-13 | Zalevsky Jonathan | Buy | 250 000 | Stock Option |
INSIDER POWER |
---|
84.96 |
Last 97 transactions |
Buy: 6 976 063 | Sell: 637 451 |
Volumen Correlación
Nektar Therapeutics Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Nektar Therapeutics Correlación - Moneda/Commodity
Nektar Therapeutics Finanzas
Annual | 2023 |
Ingresos: | $90.12M |
Beneficio Bruto: | $53.48M (59.34 %) |
EPS: | $-1.450 |
FY | 2023 |
Ingresos: | $90.12M |
Beneficio Bruto: | $53.48M (59.34 %) |
EPS: | $-1.450 |
FY | 2022 |
Ingresos: | $92.06M |
Beneficio Bruto: | $70.42M (76.50 %) |
EPS: | $-1.970 |
FY | 2021 |
Ingresos: | $101.91M |
Beneficio Bruto: | $77.01M (75.57 %) |
EPS: | $-2.86 |
Financial Reports:
No articles found.
Nektar Therapeutics
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico